Want to see TSE:DOSE full AI Analyst Report?
DOSE Stock Chart & Stats
C$0.12
<C$0.01(5.56%)
At close: 4:00 PM EDT
C$0.12
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume11.00K
Average Volume (3M)37.95K
Market Cap
C$15.01M
Enterprise ValueC$20.79
Total Cash (Recent Filing)C$14.65K
Total Debt (Recent Filing)C$5.81M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding136,444,840
10 Day Avg. Volume44,351
30 Day Avg. Volume37,951
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformThe QuickStrip platform gives Rapid Dose a defined technology base for developing pharmaceutical, nutraceutical and other delivery applications. Its licensing, development-service and product pathways could support scalable monetization without requiring a fully integrated manufacturing model.
Positive Operating Cash FlowPositive operating and free cash flow is a relative strength because it indicates some ability to fund operations internally. Although the amount is modest and sustainability is uncertain, maintaining cash generation could reduce reliance on external financing.
Asset Base GrowthGrowth in total assets suggests the company has expanded its resource base compared with 2025, potentially supporting additional development or commercialization activity. However, this benefit is limited because the capital structure remains financially stressed.
Bears Say
Declining Revenue BaseSmall and declining revenue limits operating scale, partner leverage and the ability to absorb research, regulatory and commercialization costs. Unless revenue growth becomes more consistent, the company may struggle to convert its delivery technology into durable commercial traction.
Persistent Unprofitable OperationsNegative gross profit indicates that the current revenue base does not cover direct costs, while large operating and net losses show limited economic viability. Persistent losses can consume capital and make future product development and commercialization more difficult.
Stressed Balance SheetNegative equity and meaningful debt materially reduce financial flexibility and increase solvency risk. This structure can constrain investment in the QuickStrip platform, increase dependence on financing or partners, and expose shareholders to dilution or restructuring risk.
Rapid Dose Therapeutics Corp News
DOSE FAQ
What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?
Rapid Dose Therapeutics Corp lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is Rapid Dose Therapeutics Corp’s market cap?
Rapid Dose Therapeutics Corp’s market cap is C$15.01M.
When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?
Rapid Dose Therapeutics Corp’s upcoming earnings report date is Oct 22, 2026 which is in 46 days.
How were Rapid Dose Therapeutics Corp’s earnings last quarter?
Rapid Dose Therapeutics Corp released its earnings results on Jun 29, 2026. The company reported -C$0.004 earnings per share for the quarter.
Is Rapid Dose Therapeutics Corp overvalued?
According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued.
Does Rapid Dose Therapeutics Corp pay dividends?
Rapid Dose Therapeutics Corp does not currently pay dividends.
What is Rapid Dose Therapeutics Corp’s EPS estimate?
Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapid Dose Therapeutics Corp have?
Rapid Dose Therapeutics Corp has 136,444,840 shares outstanding.
What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?
Rapid Dose Therapeutics Corp reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:DOSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.
Technical Analysis
BriaCell Therapeutics
―
Hemostemix
―
Britannia Life Sciences Inc
―
―
Telescope Innovations Corp
―